This is a retrospective real world study looking at the proportion of patients with newly diagnosed stage III/IV adenocarcinoma of the lung whose diagnostic tumour sample underwent successful EGFR mutation analysis. The gene discussed is EGFR; the disease is adenocarcinoma.